Skip to Content

New Drug Approvals Archive - April 2005

April 2005

Fosamax Plus D (alendronate and cholecalciferol) Tablets

Date of Approval: April 7, 2005
Company: Merck & Co., Inc.
Treatment for: Osteoporosis

Fosamax Plus D is a single once-weekly tablet containing the bisphosphonate drug alendronate, and seven days’ worth of vitamin D, an essential nutrient required for calcium absorption. Fosamax Plus D is used to reduce the risk of hip and spinal fractures in postmenopausal women with osteoporosis, and to increase bone mass in men with osteoporosis.

Retisert (fluocinolone acetonide) Intravitreal Implant

Date of Approval: April 8, 2005
Company: Bausch & Lomb
Treatment for: Uveitis

Retisert (fluocinolone acetonide) intravitreal implant is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Byetta (exenatide) Injection

Date of Approval: April 28, 2005
Company: Amylin Pharmaceuticals / Eli Lilly & Co.
Treatment for: Diabetes Type 2

Byetta (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.